Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $128 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated a Neutral rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $128.
June 21, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated a Neutral rating on Sarepta Therapeutics and maintained a price target of $128.
The reiteration of a Neutral rating and maintenance of the price target at $128 suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100